Cargando…

Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus

New strategies are urgently needed to address the public health threat of antimicrobial resistance. Synergistic agent combinations provide one possible pathway toward addressing this need and are also of fundamental mechanistic interest. Effective methods for comprehensively identifying synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Amar Deep, Gutheil, William G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927495/ https://www.ncbi.nlm.nih.gov/pubmed/36519895 http://dx.doi.org/10.1128/spectrum.03726-22

Ejemplares similares

Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium
por: Gargvanshi, Shivani, et al.
Publicado: (2022)

Resensitization of methicillin-resistant Staphylococcus aureus by amoxapine, an FDA-approved antidepressant
por: Wilson, Tyler J., et al.
Publicado: (2018)

Molecular docking-based screening of methicillin-resistant Staphylococcus aureus FEM proteins with FDA-approved drugs
por: Akkiraju, Anjini Gayatri, et al.
Publicado: (2023)

Synergistic Potential of Antimicrobial Combinations Against Methicillin-Resistant Staphylococcus aureus
por: Yu, Yang, et al.
Publicado: (2020)

Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus
por: Abdel-Karim, Safaa Abdel-Aal Mohamed, et al.
Publicado: (2022)

The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus
por: Yeo, Won-Sik, et al.
Publicado: (2018)

Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole
por: Mendes, Rodrigo E., et al.
Publicado: (2016)

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections
por: Maraki, Sofia, et al.
Publicado: (2023)

Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
por: Hu, Yanmin, et al.
Publicado: (2015)

Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
por: Hagihara, Mao, et al.
Publicado: (2012)

The antimicrobial activity of ceftobiprole against Methicillin-resistant Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa : A large tertiary care university hospital experience in Riyadh, Saudi Arabia
por: Altamimi, Lamees A., et al.
Publicado: (2022)

Bactericidal and Antibiotic Synergistic Effect of Nanosilver Against Methicillin-Resistant Staphylococcus aureus
por: Abdel Rahim, Khalid A. Ali, et al.
Publicado: (2015)

A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants
por: Trombetta, Ryan P., et al.
Publicado: (2018)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020
por: Duncan, Leonard R, et al.
Publicado: (2021)

Synergistic antibacterial activity between penicillenols and antibiotics against methicillin-resistant Staphylococcus aureus
por: Li, Shuihong, et al.
Publicado: (2018)

The Synergistic Antimicrobial Effect and Mechanism of Nisin and Oxacillin against Methicillin-Resistant Staphylococcus aureus
por: Wang, Jun, et al.
Publicado: (2023)

Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi
por: Planer, Joseph D., et al.
Publicado: (2014)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

In Vitro Synergistic Effect of Psidium guineense (Swartz) in Combination with Antimicrobial Agents against Methicillin-Resistant Staphylococcus aureus Strains
por: Fernandes, Tiago Gomes, et al.
Publicado: (2012)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Synergistic Effect between Cryptotanshinone and Antibiotics against Clinic Methicillin and Vancomycin-Resistant Staphylococcus aureus
por: Cha, Jeong-Dan, et al.
Publicado: (2014)

Antibiotic additive and synergistic action of rutin, morin and quercetin against methicillin resistant Staphylococcus aureus
por: Amin, Muhammad Usman, et al.
Publicado: (2015)

Synergistic antibacterial and antibiofilm effects of ultrasound and MEL-A against methicillin-resistant Staphylococcus aureus
por: Shu, Qin, et al.
Publicado: (2020)

Synergistic Antibiotic Activity of Ricini Semen Extract with Oxacillin against Methicillin-Resistant Staphylococcus aureus
por: Kim, Minjun, et al.
Publicado: (2023)

Bactericidal antibiotic-phytochemical combinations against methicillin resistant Staphylococcus aureus
por: Kyaw, Bhone Myint, et al.
Publicado: (2012)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

2129. When Is Methicillin-resistant Staphylococcus aureus not Methicillin-resistant Staphylococcus aureus?
por: Gitman, Melissa R, et al.
Publicado: (2019)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Synergistic Antibacterial Activity with Conventional Antibiotics and Mechanism of Action of Shikonin against Methicillin-Resistant Staphylococcus aureus
por: Li, Qian-Qian, et al.
Publicado: (2022)

An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)
por: Lau, Qiu Ying, et al.
Publicado: (2015)

In Vitro Synergistic Inhibitory Effects of Plant Extract Combinations on Bacterial Growth of Methicillin-Resistant Staphylococcus aureus
por: Jeong, Jae-Young, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

Anthracimycin Activity Against Contemporary Methicillin-Resistant Staphylococcus aureus
por: Hensler, Mary E., et al.
Publicado: (2014)

Antibacterial potential of Malaysian ethnomedicinal plants against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA)
por: Yi Xin, Low, et al.
Publicado: (2021)

Antimicrobial-drug use and methicillin-resistant Staphylococcus aureus.
por: Monnet, D L, et al.
Publicado: (2001)

Computational Screening of Approved Drugs for Inhibition of the Antibiotic Resistance Gene mecA in Methicillin-Resistant Staphylococcus aureus (MRSA) Strains
por: Otarigho, Benson, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9813ci4028tm5b9lm6tqfp87qo